| Merck Explores KRAS Inhibitors with US$2.55 B Taisho/Astex Deal |
Abstract
html
pdf
|
|
Michelle Liu |
|
| Incyte Pays US$900 M Upfront to Partner with MorphoSys for Tafasitamab |
Abstract
html
pdf
|
|
Michelle Liu |
|
| Astellas Partners with Adaptimmune on “Off-the-shelf” Cell Therapies |
Abstract
html
pdf
|
|
Michelle Liu |
|
| Sanofi Adds Depth to its Pipeline with US$2.6 B Nurix Collaboration |
Abstract
html
pdf
|
|
Subham Nandi |
|
| Ionis Signs Discovery Deals with Empirico and Aro |
Abstract
html
pdf
|
|
Pratika Pahwa |
|
| Boehringer Ingelheim Buys Rights to Enleofen’s Fibro-inflammatory Anti-IL-11 Platform |
Abstract
html
pdf
|
|
Michelle Liu |
|
| Roche In-licenses Amunix’s Half-life Extension Technology in US$1.5 B Deal |
Abstract
html
pdf
|
|
Sharath Chandra Nakka |
|
| Pfizer Licenses eFFECTOR's eIF4E Inhibitors to Bolster Oncology Pipeline |
Abstract
html
pdf
|
|
Neha Madhwani |
|
| Gilead Collaborates with Kyverna Therapeutics on T-cell Therapies |
Abstract
html
pdf
|
|
Pratika Pahwa |
|
| Lilly Pays US$1.1 B for Dermatology-Focused Dermira |
Abstract
html
pdf
|
|
Michelle Liu |
|
| BioNTech Acquires Struggling Neon for US$67 M |
Abstract
html
pdf
|
|
Michelle Liu |
|
| Astellas Continues Gene and Cell Therapy Acquisition Trend with Xyphos Buy |
Abstract
html
pdf
|
|
Jawala Prasad |
|
| Allergan Divests Brazikumab and Zenpep to Move Forward with AbbVie Acquisition |
Abstract
html
pdf
|
|
Michelle Liu |
|
